Investing.com - Cyteir Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Cyteir Therapeutics announced earnings per share of $-0.31 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.40 on revenue of $0.00.
Cyteir Therapeutics shares are down 5.02% from the beginning of the year, still down 90.08% from its 52 week high of $17.65 set on November 11, 2021.
Cyteir Therapeutics follows other major Healthcare sector earnings this month
Cyteir Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar